San Diego, CA, March 29, 2016 — Nobilis Therapeutics, Inc. announced today an entry into an exclusive agreement with Harvard University’s Partners Healthcare to license intellectual property surrounding the use of noble gas-containing mixtures as a treatment for Post-Traumatic Stress Disorder (PTSD). The agreement gives Nobilis Therapeutics the rights to the treatment of PTSD as well as of other psychiatric disorders.
The use of Noble gas-containing mixtures to treat PTSD was pioneered by researchers at Harvard-affiliated McLean Hospital, including Dr. Edward Meloni, PhD, an Assistant Professor of Psychiatry. Dr. Meloni’s recent animal study had decisively demonstrated a significant reduction in fear symptoms after exposure to noble gas-containing gas mixture .
“The therapeutic potential of noble gas based therapeutics is difficult to overestimate”, said Dr. Meloni. “We are excited to work with the team of Nobilis Therapeutics, who have years of clinical development experience in the area of experimental therapeutics, to bring this promising therapy as quickly as possible to patients.”
“This license agreement adds to Nobilis Therapeutics’ growing IP portfolio that centers around noble gas applications,” stated Dr. Vlad Bogin, CEO of Nobilis Therapeutics. “We believe that noble gas-containing therapy has a tremendous potential to reduce the burden of many psychiatric and neurodegenerative diseases and are excited to work with Dr. Meloni and his colleagues on launching a clinical trial on its use in PTSD treatment this year.”
PTSD is a mental health disorder that is triggered by witnessing or living though a terrifying event. Symptoms include severe anxiety, flashbacks and nightmares that are extremely difficult to treat. The lifetime prevalence of PTSD in adult US population has been reported to range between 6.8 and 12.3 per cent. It is estimated that in veteran population PTSD leads to more than 22 suicides per day, an unsettling number.
About Nobilis Therapeutics
Nobilis Therapeutics, LLC is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using controlled device administration of inert gases that have exceptional safety profile proven by decades of clinical use.
Vlad Bogin, MD, FACP
9255 Towne Centre Drive Suite 450
San Diego, CA 92121
Tel: (971) 229-1679
About Nobilis Therapeutics:
Vlad Bogin, MD, FACP is an expert in the field of clinical research and early biotech start ups. He is the founder of Cromos Pharma, a premier regional CRO and a former President and Chairman of the board of Medistem (MEDS), a biotech company acquired by Intrexon (XON).